Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis
Bixin Ren, Jiucheng Shen, Yajuan Qian, Tong Zhou
Abstract
OBJECTIVE: The impact of pre-immunotherapy sarcopenia in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) is elusive. We performed a meta-analysis to investigate the association between sarcopenia and clinical outcomes of ICIs. METHODS: PubMed, EMBASE, and the Cochrane Library were searched. RESULTS: = 0.18. CONCLUSION: Pre-immunotherapy sarcopenia was associated with poor clinical outcomes in patients with advanced NSCLC who received ICIs.
Topics & Concepts
MedicineSarcopeniaInternal medicineLung cancerOdds ratioConfidence intervalMeta-analysisImmunotherapyCochrane LibraryOncologyClinical trialGastroenterologyCancerCancer Immunotherapy and BiomarkersNutrition and Health in AgingInflammatory Biomarkers in Disease Prognosis